Advancing Treatment Horizons for Stargardt Disease and Geographic Atrophy

According to reports from Ophthalmology Times Europe, the European Medicines Agency (EMA) and its Committee for Advanced Therapies (CAT) have provided a positive opinion for the Advanced Therapy Medicinal Product (ATMP) classification of two gene therapy candidates: OCU410 and OCU410ST. This regulatory milestone is of significant interest to the inherited retinal disease (IRD) community, particularly patients and families navigating the challenges of Stargardt disease and dry age-related macular degeneration.

Key Details from the Source Material

Developed by Ocugen, both gene therapy candidates utilize an adeno-associated virus (AAV) platform to deliver a novel modifier gene via a single subretinal injection. According to the source:

  • OCU410 is intended to treat vision loss associated with geographic atrophy (GA), an advanced form of dry age-related macular degeneration. Preliminary 9-month data indicated lower lesion growth and clinically meaningful visual function gains.
  • OCU410ST is being developed for Stargardt disease, an inherited condition linked to ABCA4-related retinopathies. Phase 1 data showed slower lesion growth in treated eyes compared to untreated fellow eyes, alongside visual improvements.

The ATMP classification is designed to accelerate regulatory review timelines in Europe and provides developers with enhanced scientific guidance and protocol assistance from the EMA.

What This Means for Patients and Families

For families affected by Stargardt disease and geographic atrophy, regulatory recognitions like the EMA's positive ATMP opinion mark important steps forward in the development pipeline. Stargardt disease currently has no globally approved treatments, while geographic atrophy options often require frequent, ongoing dosing. A potential one-and-done subretinal gene therapy approach aims to address underlying pathways while reducing the treatment burden for patients.

As clinical development continues, stakeholders across the IRD community will be closely following subsequent trial phases and future regulatory filings as these therapies progress.